$ News

Verve Therapeutics (VERV) Reported Results From its Heart-2 Phase 1b Trial for VERVE-102

Biotech Stocks Are Ready to Rebound. 3 to Watch Now.

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

Verve Therapeutics downgraded to Hold from Buy at Canaccord

Lock In The 81.5% Run: Initiating Verve With A Sell

Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports

What Makes Verve Therapeutics (VERV) a New Buy Stock

Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average

Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High?

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Verve Therapeutics to Participate in Upcoming Investor Conferences

3 Top Genomics Stocks to Add to Your Portfolio in 2025

Analyst Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates

Verve Therapeutics: Q1 Earnings Snapshot

Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street

Why Verve Therapeutics Zoomed 40% Higher This Week

Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'